SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, disclosed today that it has filed a provisional patent submission entitled, “Method and Apparatus for Increasing Contaminant Clearance Rates during Extracorporeal Fluid Treatment,” with the U.S. Patent and Trademark Office (USPTO). The patent describes technical improvements to the Aethlon Hemopurifier® that increase the rate of capture of undesirable blood contaminants including viruses, toxins, and immunosuppressive particles associated with cancer.
